Literature DB >> 8930981

Degradation of Alzheimer's beta-amyloid protein by human cathepsin D.

J R McDermott1, A M Gibson.   

Abstract

The aim of the study was to identify and characterize human brain peptidases capable of degrading Alzheimer's beta-amyloid protein. Synthetic beta-amyloid protein (1-40) was rapidly degraded by a human brain soluble fraction, optimum activity occurring at around pH4. Pepstatin totally inhibited the activity showing that an aspartyl protease was responsible. HPLC separation and identification of the degradation products showed that the L34-M35 bond was the primary site of cleavage followed by hydrolysis of the F19-F20 and F20-A21 bonds. The major lysosomal aspartyl protease, cathepsin D, hydrolysed beta-amyloid protein with the same pH profile, inhibitor sensitivity and bond specificity as the activity present in human brain soluble fraction. We suggest that cathepsin D may play an important role in regulating brain concentrations of beta-amyloid protein (1-40).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930981     DOI: 10.1097/00001756-199609020-00021

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  18 in total

Review 1.  Microglial functions and proteases.

Authors:  Hiroshi Nakanishi
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

Review 2.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

3.  Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.

Authors:  K Vekrellis; Z Ye; W Q Qiu; D Walsh; D Hartley; V Chesneau; M R Rosner; D J Selkoe
Journal:  J Neurosci       Date:  2000-03-01       Impact factor: 6.167

Review 4.  Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration.

Authors:  Wesley Peng; Georgia Minakaki; Maria Nguyen; Dimitri Krainc
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

5.  Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.

Authors:  J R McDermott; A M Gibson
Journal:  Neurochem Res       Date:  1997-01       Impact factor: 3.996

Review 6.  Proteolytic degradation of amyloid β-protein.

Authors:  Takaomi Saido; Malcolm A Leissring
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

7.  Poloxamer-188 Exacerbates Brain Amyloidosis, Presynaptic Dystrophies, and Pathogenic Microglial Activation in 5XFAD Mice.

Authors:  Antonio Di Meco; Shahrnaz Kemal; Jelena Popovic; Sidhanth Chandra; Katherine Sadleir; Robert Vassar
Journal:  Curr Alzheimer Res       Date:  2022       Impact factor: 3.040

Review 8.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

9.  Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain.

Authors:  S A Frautschy; D L Horn; J J Sigel; M E Harris-White; J J Mendoza; F Yang; T C Saido; G M Cole
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

10.  GPR120 signaling controls amyloid-β degrading activity of matrix metalloproteinases.

Authors:  Kazunori Kikuchi; Takuya Tatebe; Yuki Sudo; Miyabishara Yokoyama; Kiwami Kidana; Yung Wen Chiu; Sho Takatori; Makoto Arita; Yukiko Hori; Taisuke Tomita
Journal:  J Neurosci       Date:  2021-06-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.